PE20211463A1 - Compuestos de aminoacidos y metodos de uso - Google Patents
Compuestos de aminoacidos y metodos de usoInfo
- Publication number
- PE20211463A1 PE20211463A1 PE2021000461A PE2021000461A PE20211463A1 PE 20211463 A1 PE20211463 A1 PE 20211463A1 PE 2021000461 A PE2021000461 A PE 2021000461A PE 2021000461 A PE2021000461 A PE 2021000461A PE 20211463 A1 PE20211463 A1 PE 20211463A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- cycloalkyl
- alkyl
- alkylene
- compounds
- Prior art date
Links
- -1 AMINO ACID COMPOUNDS Chemical class 0.000 title abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 108010004686 integrin alphavbeta1 Proteins 0.000 abstract 1
- 108010004788 integrin alphavbeta6 Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| PCT/US2019/055252 WO2020076862A1 (en) | 2018-10-08 | 2019-10-08 | Amino acid compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211463A1 true PE20211463A1 (es) | 2021-08-05 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000461A PE20211463A1 (es) | 2018-10-08 | 2019-10-08 | Compuestos de aminoacidos y metodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11180494B2 (enExample) |
| EP (1) | EP3863711A4 (enExample) |
| JP (1) | JP7523450B2 (enExample) |
| KR (1) | KR20210101205A (enExample) |
| CN (1) | CN113195053B (enExample) |
| AU (1) | AU2019358041A1 (enExample) |
| BR (1) | BR112021006620A2 (enExample) |
| CA (1) | CA3115643A1 (enExample) |
| CL (2) | CL2021000863A1 (enExample) |
| CO (1) | CO2021004279A2 (enExample) |
| CR (1) | CR20210224A (enExample) |
| CU (1) | CU24690B1 (enExample) |
| DO (1) | DOP2021000054A (enExample) |
| EA (1) | EA202190967A1 (enExample) |
| EC (1) | ECSP21032717A (enExample) |
| IL (1) | IL282026A (enExample) |
| JO (1) | JOP20210056A1 (enExample) |
| MX (1) | MX2021004015A (enExample) |
| PE (1) | PE20211463A1 (enExample) |
| PH (1) | PH12021550784A1 (enExample) |
| SG (1) | SG11202103283RA (enExample) |
| TW (1) | TW202028179A (enExample) |
| WO (1) | WO2020076862A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2024145245A2 (en) * | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
| GB202301024D0 (en) * | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN122270455A (zh) * | 2023-12-22 | 2026-06-23 | 北京炫景瑞医药科技有限公司 | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20100037600A (ko) | 2007-06-13 | 2010-04-09 | 브리스톨-마이어스 스큅 컴퍼니 | 응고 인자 억제제로서의 디펩티드 유사체 |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| LT3275883T (lt) | 2015-03-25 | 2021-08-25 | Fujifilm Corporation | Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba |
| KR20190026001A (ko) | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| EP3843728B1 (en) | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en not_active Abandoned
- 2019-10-08 JP JP2021544112A patent/JP7523450B2/ja active Active
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en not_active Withdrawn
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en not_active Ceased
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053B/zh active Active
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko not_active Ceased
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
- 2023-12-19 US US18/545,952 patent/US20240270742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115643A1 (en) | 2020-04-16 |
| CO2021004279A2 (es) | 2021-04-30 |
| AU2019358041A1 (en) | 2021-05-20 |
| US11952376B2 (en) | 2024-04-09 |
| US20200109141A1 (en) | 2020-04-09 |
| CL2021000863A1 (es) | 2021-09-10 |
| CN113195053B (zh) | 2024-08-30 |
| PH12021550784A1 (en) | 2021-10-25 |
| US20220144829A1 (en) | 2022-05-12 |
| EP3863711A4 (en) | 2022-07-06 |
| EP3863711A1 (en) | 2021-08-18 |
| CN113195053A (zh) | 2021-07-30 |
| SG11202103283RA (en) | 2021-04-29 |
| DOP2021000054A (es) | 2021-08-31 |
| MX2021004015A (es) | 2021-06-23 |
| IL282026A (en) | 2021-05-31 |
| WO2020076862A1 (en) | 2020-04-16 |
| JOP20210056A1 (ar) | 2021-03-24 |
| CL2023001331A1 (es) | 2023-10-20 |
| ECSP21032717A (es) | 2021-06-30 |
| KR20210101205A (ko) | 2021-08-18 |
| CU20210027A7 (es) | 2021-11-04 |
| JP7523450B2 (ja) | 2024-07-26 |
| US20240270742A1 (en) | 2024-08-15 |
| BR112021006620A2 (pt) | 2021-07-06 |
| TW202028179A (zh) | 2020-08-01 |
| EA202190967A1 (ru) | 2021-09-17 |
| JP2022508657A (ja) | 2022-01-19 |
| CR20210224A (es) | 2021-06-08 |
| US11180494B2 (en) | 2021-11-23 |
| CU24690B1 (es) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000054A (es) | Compuestos de aminoácidos y métodos de uso /amino acid compounds and methods of use | |
| PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
| ECSP20063227A (es) | Compuestos de aminoácidos y métodos de uso | |
| BR112015018317A8 (pt) | Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| UY36201A (es) | Herbicidas de piperidinona | |
| PH12020550921A1 (en) | Cap-dependent endonuclease inhibitors | |
| CO2017012518A2 (es) | Derivados de 2-(feniloxi o feniltio) pirimidina como herbicidas | |
| CR20160548A (es) | Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1 | |
| PE20142340A1 (es) | Inhibidores de bromodominios | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| MX2016011358A (es) | Composiciones liquidas de lactasa. | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| DOP2019000169A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1 | |
| EP3781574A4 (en) | MACROCYCLIC SPIROETHER AS MCL-1 INHIBITORS | |
| BR112022011690A2 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer, método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas e invenção | |
| CY1123527T1 (el) | Αντιφυματικος παραγοντας | |
| BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
| AR051315A1 (es) | Pirimidinas 5-sustituidas inhibidoras del vih | |
| EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок |